Cydan Overview
- Year Founded
-
2013
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
Cydan General Information
Description
Operator of an orphan drug accelerator intended to create therapies that improve the lives of patients living with rare genetic diseases. The company accelerates therapies through clinical, regulatory, and commercial development for treating patients with rare diseases, with approved treatments, enabling patients and families with rare diseases to be treated in a salutary way and helping them recover soon.
Contact Information
Website
www.cydanco.comCorporate Office
- 700 Technology Square
- 3rd Floor
- Cambridge, MA 02139
- United States
Corporate Office
- 700 Technology Square
- 3rd Floor
- Cambridge, MA 02139
- United States
Cydan Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 31-Dec-2021 | Completed | Out of Business | |||
| 2. Early Stage VC | 17-Oct-2017 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 01-Oct-2013 | $26M | $26M | Completed | Startup |
Cydan Patents
Cydan Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210338782-A1 | Storage stable somatostatin-dopamine chimeric compounds and salt forms thereof | Inactive | 04-Oct-2019 | ||
| US-20200157108-A1 | Methods of making and using pde9 inhibitors | Active | 26-May-2017 | ||
| US-20230183244-A1 | Methods of making and using pde9 inhibitors | Active | 26-May-2017 | ||
| US-11999741-B2 | Process for the synthesis of 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one | Active | 26-May-2017 | ||
| US-20250019381-A1 | Process for the synthesis of 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one | Inactive | 26-May-2017 | C07D487/04 |
Cydan Signals
Cydan Investments (4)
Cydan’s most recent deal was a Early Stage VC with Tiburio Therapeutics for . The deal was made on 03-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tiburio Therapeutics | 03-Jan-2019 | Early Stage VC | Biotechnology | ||
| Hyasynth | 13-Jul-2016 | Accelerator/Incubator | Other Pharmaceuticals and Biotechnology | ||
| HIVE Biosystems | 24-Jun-2015 | Accelerator/Incubator | Discovery Tools (Healthcare) | ||
| Vtesse | Accelerator/Incubator | Drug Discovery |
Cydan FAQs
-
When was Cydan founded?
Cydan was founded in 2013.
-
Where is Cydan headquartered?
Cydan is headquartered in Cambridge, MA.
-
What is the size of Cydan?
Cydan has 6 total employees.
-
What industry is Cydan in?
Cydan’s primary industry is Drug Discovery.
-
Is Cydan a private or public company?
Cydan is a Private company.
-
What is Cydan’s current revenue?
The current revenue for Cydan is .
-
How much funding has Cydan raised over time?
Cydan has raised $60M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process